Children with CKD have a significant burden, including fatigue and sleep disturbances.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Children with CKD have a significant burden, including fatigue and sleep disturbances.

Latest News

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD Brad Rovin, MD

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Latest News

News All Time

Why IgA Nephropathy Risk Stratification Still Falls Short Ali Mehdi, MD, MEd

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD Alexander Combes, PhD

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial Abigail Brooks, MA

New ESC, ERA Guideline Calls for Universal CKD Screening in Cardiovascular Disease Abigail Brooks, MA

Diagnosis to Data: What Patient Experience Adds to IgAN Research Bryon Wade

Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data Alex Hillenbrand

FAQ: Understanding New ESC/ERA Guideline on Cardiovascular Disease and Chronic Kidney Disease Patrick Campbell

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD Alexander Combes, PhD

Inaxaplin Cuts Proteinuria in Broader APOL1 Kidney Disease Population Alex Hillenbrand

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD Abigail Brooks, MA

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care George Vasquez-Rios, MD

Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

Recommended News For You

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

For relapsed or resistant DLBCL, odronextamab produced positive results.

Could Burnout Become the Employer’s Responsibility?

How access to specialized cancer centers affects glioblastoma outcomes

Abemaciclib Slows Progression of Advanced Liposarcoma

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Recommended Articles For You

Advanced Pathways in Oncology for Better Care

Molecular & Genetic Oncology: Emerging Frontiers in 2025

Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies

Hematopoietic Aging and Functional Blood Health: Mechanisms, Clinical Implications, and Advances

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.